GlassScriptPhysician profile
Kootaybah Alsheikhly
NPI 1376079384
$8,014.09
in general payments reported to CMS, 2019-2025
32 companies · $811 in 2025
The $811 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $152 · 2021: $1,768 · 2022: $3,027 · 2023: $597 · 2024: $1,659 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $1,958.79 | 2022-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $1,472.97 | 2021-2024 | Optis, Aveir, Nc Trek Neo |
| Kestra Medical Technology Services, INC. | $745.06 | 2023-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $467.09 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $388.98 | 2021-2025 | Lifevest |
| Amgen INC. | $349.69 | 2021-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $250.00 | 2021-2022 | |
| Medtronic, INC. | $229.00 | 2022-2024 | Venaseal |
| Astrazeneca Pharmaceuticals LP | $227.46 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $179.53 | 2025 | Eliquis, Camzyos |
| Heartflow, INC. | $168.67 | 2024 | |
| Novartis Pharmaceuticals Corporation | $140.55 | 2023-2025 | |
| Boston Scientific Corporation | $139.49 | 2024 | Watchman Flx |
| Cathworks, INC. | $137.02 | 2022 | |
| Philips North America LLC | $129.54 | 2022-2025 | (5044) Mcot, Eagle Eye |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $128.65 | 2024 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $101.15 | 2023-2024 | Verquvo |
| Truvic Medical, INC. | $100.00 | 2022 | |
| Pfizer INC. | $99.27 | 2023-2025 | |
| Shockwave Medical, INC | $82.50 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Daiichi Sankyo INC. | $69.26 | 2023-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $66.20 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $41.17 | 2023 | Optimizer |
| Cordis US Corp. | $40.08 | 2023-2024 | Mynx Control, Zephyr |
| Scpharmaceuticals INC. | $29.63 | 2023-2024 | |
| Cardiva Medical, INC. | $27.73 | 2022 | |
| Edwards Lifesciences Corporation | $26.04 | 2025 | Sapien 3 Ultra Resilia |
| Terumo Medical Corporation | $25.45 | 2023 | Angio-Seal |
| Actelion Pharmaceuticals US, INC. | $24.63 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $23.14 | 2023 | Arcalyst |
| Novo Nordisk INC | $20.35 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kootaybah Alsheikhly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.